Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2024: 25.17%

Hikma Pharmaceuticals PLC EBITDA Margin is 25.17% for the year ending December 31, 2024, a -8.52% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2023 was 27.51%, a 42.78% change year over year.
  • Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2022 was 19.27%, a -33.88% change year over year.
  • Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2021 was 29.14%, a 4.31% change year over year.
  • Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2020 was 27.94%, a 5.58% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin